Basel, Switzerland, 5 February 2010 – Lonza recently presented the newest nutritional bars containing Carnipure™, its branded L-Carnitine health ingredient, at the third annual Healthy & Nutritional Bars Conference in Cologne, Germany. Developed for health-conscious, active consumers, the bars provide a quick snack formulated with a proven energy production ingredient.
Under the brand Carnipure™, Lonza offers Carnipure™ crystalline, which is pure L-Carnitine, as well as Carnipure™ tartrate, a non-hygroscopic form made of L-Carnitine and tartaric acid. Both forms are suitable for use in nutritional bars. Products displaying the Carnipure™ Quality Seal on the packaging show the consumer that they contain only L-Carnitine from Lonza Ltd, Switzerland.
L-Carnitine is a nutrient that is both produced in the body and can be found in some dietary sources. It plays a critical role in fat and energy metabolism by carrying long-chain fatty acids into the cells’ mitochondria where they are broken down for energy generation. Extensive research has shown that Carnipure™ can offer many important benefits including acceleration of post-exercise recovery and an increase in energy metabolism.
Lonza was a sponsor of the Healthy & Nutritional Bars Conference, which was organized by Bridge2Food, a knowledge and network agency based in the Netherlands. Over 90 representatives from the food and nutrition industry participated in the event, which took place on February 3-4, alongside the ISM, the world’s largest and most important confectionery trade fair.
More information on products with Carnipure™ can be found on www.carnipure-for-you.com.
Lonza is one of the world's leading suppliers to the pharmaceutical, healthcare and life science industries. Its products and services span its customers’ needs from research to final product manufacture. Lonza is the global leader in the production and support of active pharmaceutical ingredients both chemically as well as biotechnologically. Biopharmaceuticals are one of the key growth drivers of the pharmaceutical and biotechnology industries. Lonza has strong capabilities in large and small molecules, peptides, amino acids and niche bioproducts which play an important role in the development of novel medicines and healthcare products. Lonza is a leader in cell-based research, endotoxin detection and cell therapy manufacturing. Lonza is also a leading provider of value chemical and biotech ingredients to the nutrition, hygiene, preservation, agro and personal care markets.
Lonza is headquartered in Basel, Switzerland and is listed on the SIX Swiss Exchange. In 2009, Lonza had sales of CHF 2.69 billion. Further information can be found at www.lonza.com.